Investigation of the types of intestinal microbiota in patients with insulin resistance in the Kazakh population

Individual registration number АР14871581

Execution period - 2022 -2024

Funding source - Ministry of Science and Higher Education of the Republic of Kazakhstan (contract No. 176/30-22-24 of October 18, 2022).

The head of the temporary scientific team is Abildinova Gulshara Zhusupovna.

Aim of the project. To determine the predictive value of the species diversity of the intestinal microbiota in case of insulin resistance in the Kazakh population.

Project tasks.

Collection and compilation of phenotypic and genotypic data on 200 study participants;
Study of phenotypic associations of study participants using the structure of intestinal microbiota based on sequencing of the 16s ribosomal RNA gene;
Formation of conclusions about the possibility of managing insulin resistance in the Kazakh population by modifying the species structure of the intestinal microbiome.

Expected results.

Based on new scientific data, additional opportunities for the management of insulin resistance in the Kazakh population through the modification of the species structure of the intestinal microbiota in the Kazakh population;
2 publications in a peer-reviewed scientific publication indexed in the Science Citation Index Expanded Web of Science database and (or) having a citescore percentile in the Scopus database of at least 35, 1 article in a peer-reviewed foreign or domestic publication recommended by CCES, abstracts and 2 reports on international scientific and practical conferences, guidelines.

Study of Gut Microbiome Structure and Its Association with Insulin Resistance (2023–2024)

1. Gut Microbiome Profiling Methodology

The structure of the gut microbiome in this study was determined based on the extraction of total bacterial DNA and sequencing of variable regions V2-4-8 and V3-6,7-9, as well as V3-V4 of the 16S ribosomal RNA gene.

DNA was extracted from stool samples, and library preparation and amplification of the variable regions were carried out using the Ion 16S™ Metagenomics Kit on the Ion Gene Studio S5 Plus system (USA), following the manufacturer’s protocols.
The amplified fragments were sequenced using the Ion PGM Sequencing 400 Kit on the Ion PGM platform, and data were analyzed using the Ion 16S™ metagenomic analysis module in Ion Reporter software.

2. Genotypic and Phenotypic Data Analysis

Phenotypic and genotypic data were collected and analyzed for 200 study participants.
The phenotypic database contains 87 characteristics, while the genotypic database includes taxonomic identification of key bacterial groups classified by class and species.
A comparative evaluation of the relative abundance of specific bacterial species was performed between the control and study groups.

3. Scientific Interpretation and Complex Analysis

A comprehensive scientific interpretation was conducted, including a multi-parameter analysis of the gut microbiota across the study groups.
A multifactorial assessment of gut microbiome profiles was conducted on 295 patients, providing a robust scientific foundation for international publications indexed in SCOPUS and Web of Science.

4. Scientific Output Aligned with the 2023–2024 Research Plan

Publications:

1. Review Article published in Frontiers in Medicine (Gastroenterology section):
Title: Global Trends and Collaborative Networks in Gut Microbiota–Insulin Resistance Research: A Comprehensive Bibliometric Analysis (2000–2024)

Manuscript ID: 1452227
Authors: Gulshara Zh. Abildinova, Valeriy V. Benberin, Tamara Vochshenkova, Alireza Afshar, Nadiar M. Mussin, Asset Kaliyev, Zhanna Zhussupova, Amin Tamadon
Submission Date: 20 June 2024
SCOPUS Percentile: 85
Type: Review Article

Patent:

Kazakhstan Patent on Utility Model

Title: Method for Predicting the Risk of Insulin Resistance in the Kazakh Population

Patent Number: 9081
IPC: G01N 33/00, G01N 33/48 (2006.01)
Bulletin Number and Date: No. 18, May 3, 2024

5. Scientific Presentations and Conferences

Poster Presentations:

1. European Society of Human Genetics, Berlin (June 4–6, 2024):

Title: Relationship of the species ratio of bacteria and the effectiveness of therapy for arterial hypertension in men and women with insulin resistance
Session: ER07.007

2. Dubai WordLab IFCC Congress (May 26–30, 2024):

Title: Relationship between gut microbiome and cardiovascular pathology in patients with insulin resistance

Invited Talks:

3. Nobel Fest, Astana (April 27–28, 2024):

Speaker: G.Zh. Abildinova
Talk: Species Characteristics of the Microbiome

4. II International Conference “Healthy Generation – Future of Kazakhstan”, Almaty (June 13–14, 2024):

Talk: Modern Aspects of Gut Microbiome Significance
Speaker: G.Zh. Abildinova

6. Methodological Guidelines Developed

Title: Gut Microbiome and Markers of Insulin Resistance

ISBN: 978-601-7078-16-4
Developed based on the results of this study, the guidelines provide practical recommendations for the assessment and clinical use of gut microbiota data in predicting insulin resistance.

Contact Information:
Gulshara Zhussupovna Abildinova
Phone: +7 (7172) 70-80-90, ext. 8134